What laboratory tests should be obtained before initiating testosterone injection therapy in a 48-year-old male?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: August 21, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Baseline Laboratory Testing Before Testosterone Therapy

Before starting testosterone injections in a 48-year-old male, you must obtain: baseline testosterone level (measured on two separate mornings), hematocrit, PSA, and digital rectal examination. 1

Essential Pre-Treatment Labs

Testosterone Measurement

  • Two separate fasting morning total testosterone levels are required to confirm hypogonadism 1
  • Both measurements should be below 300 ng/dL (10.4 nmol/liter) to establish deficiency
  • Morning samples are critical because testosterone levels fluctuate throughout the day
  • If total testosterone is borderline or conditions affecting SHBG exist (obesity, diabetes, aging), consider adding free testosterone measurement 2

Hematocrit/Hemoglobin

  • Baseline hematocrit is mandatory 1
  • Hematocrit >50% is a relative contraindication to therapy and requires further evaluation before initiating treatment 1
  • Testosterone causes dose-dependent increases in hemoglobin, with greater increases in older men 1
  • If hematocrit exceeds 54% during treatment, therapy must be stopped 1

Prostate Screening (Critical for 48-Year-Old)

  • PSA level and digital rectal examination are required before starting therapy 1, 3
  • At age 48, this patient falls into the category requiring prostate screening (men ≥40 years old with baseline PSA >0.6 ng/mL) 1
  • The 2010 Endocrine Society guidelines specifically state screening for men 40 years or older 1
  • Any PSA >4.0 ng/mL or abnormal digital rectal examination requires prostate biopsy before initiating testosterone 4
  • This is non-negotiable - the FDA label explicitly requires evaluation for prostate abnormalities before treatment 5

Additional Baseline Assessments

Clinical Evaluation

  • Document baseline voiding symptoms using standardized questionnaire (AUA/IPSS score) 4
  • Screen for sleep apnea history 4, 5
  • Assess for benign prostatic hypertrophy symptoms 5

Optional But Recommended Labs

While not explicitly mandated by the highest-quality guidelines, consider:

  • Lipid panel (serum cholesterol may increase during therapy) 5
  • Liver function tests if considering long-term therapy (rare hepatocellular carcinoma risk) 5
  • Thyroid function if clinically indicated (androgens may affect thyroid binding globulin) 5

Common Pitfalls to Avoid

Do not start testosterone if:

  • Only one testosterone measurement was obtained (need two separate morning samples)
  • Hematocrit is >50% without further evaluation 1
  • PSA or digital rectal examination is abnormal without urological clearance
  • Patient has untreated prostate or breast cancer 6
  • Patient has severe heart failure 6

Critical timing issue: The 2006 guidelines recommended PSA screening for all men before treatment 3, but the 2010 update refined this to men ≥40 years with PSA >0.6 ng/mL 1. Given your patient is 48 years old, both PSA and digital rectal examination are mandatory regardless of baseline PSA value, as this represents the most conservative and safest approach.

Monitoring Algorithm After Initiation

Once baseline labs are obtained and therapy starts:

  • Recheck testosterone, hematocrit, and PSA at 3 months 1
  • Then monitor annually thereafter 1
  • Stop therapy immediately if hematocrit exceeds 54% 1
  • Obtain urology referral if PSA increases >1.4 ng/mL within any 12-month period 1

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.